Trials / Completed
CompletedNCT00044798
Magnetic Stimulation Therapy for Treating Vascular Depression
Vascular Depression and Magnetic Stimulation Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 132 (estimated)
- Sponsor
- University of Iowa · Academic / Other
- Sex
- All
- Age
- 51 Years – 89 Years
- Healthy volunteers
- Not accepted
Summary
This 12-week study will evaluate the effectiveness of repetitive transcranial magnetic stimulation (rTMS) of the brain, followed by citalopram (Celexa®), for treatment of depression associated with small vascular lesions in the brain (vascular depression).
Detailed description
Vascular depression is a condition that typically affects the elderly and is associated with small vascular lesions. It is more resistant to treatment and has a poorer outcome than nonvascular depression. By altering excitability in the cortical area of the brain, rTMS may be an effective treatment neuropsychiatric conditions, particularly depression. Participants in this study will be randomly assigned to 15 treatments of either rTMS or sham rTMS for 3 weeks. Following treatment, participants will receive citalopram for 9 weeks. Response rates to treatment; relapse rates; the size, number, and location of the vascular lesions; and the amount of regional brain atrophy will be measured. Improvements in activities of daily living, quality of life, and cognitive function will also be also measured.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Repetitive transcranial magnetic stimulation (rTMS) | Participants will receive 15 treatments of rTMS over 3 weeks. |
| DRUG | Citalopram | After completing treatment with rTMS or sham rTMS, participants will take citalopram for 9 weeks. |
| PROCEDURE | Sham rTMS | Participants will receive 15 treatments of sham rTMS over 3 weeks. |
Timeline
- Start date
- 2001-09-01
- Primary completion
- 2007-03-01
- Completion
- 2008-08-01
- First posted
- 2002-09-06
- Last updated
- 2013-09-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00044798. Inclusion in this directory is not an endorsement.